Lebanese Hospital-Based Rheumatoid Arthritis Registry: Characteristics of Patients and Comparison with Other Populations
- PMID: 36128213
- PMCID: PMC9450197
- DOI: 10.31138/mjr.33.2.218
Lebanese Hospital-Based Rheumatoid Arthritis Registry: Characteristics of Patients and Comparison with Other Populations
Abstract
Objectives: The aim of the Lebanese hospital-based Rheumatoid Arthritis (RA) registry, initiated in 2011, is to evaluate the safety and efficacy of biologic agents among patients seeking care at the American University of Beirut Medical Center (AUBMC). We aimed to characterize the demographic and clinical profile of RA patients included in the Lebanese registry. We compared our results with those issued from Middle Eastern and non-Middle Eastern registries.
Methods: 195 Patients enrolled in the RA registry from 2011 to 2018 were considered in this study. Patients enrolled in the registry were eligible to be treated with biologics, but 56 patients remained biologics naïve. Patients were reassessed every six months.
Results: The highest proportion of patients were female (81%). The mean age was 55.53±15 years, and the disease duration was 11.38±7.7 years. RA was diagnosed at a mean age of 44.13±16 years. Almost one-third of RA patients were smokers (29.2%) and 15% consumed alcohol. Comorbidities included cardiac diseases (30.8%), hypertension (24.6%), hyperlipidemia (11.8%), diabetes mellitus (9.2%), and Hypothyroidism (6.2%). Three cases of cancer and seven cases of tuberculosis were reported. The mean of the Disease Activity Score (DAS28) was 3.75 ± 2.28 with no difference according to gender; the mean of the Health Assessment Questionnaire (HAQ) score showed a significant difference between females and males (1.02 ± 0.84 and 0.61 ± 0.7 respectively). Methotrexate was the most commonly used medication. There was non-significant difference in taking biologics according to gender.
Conclusion: Our findings are similar to other studies in terms of gender distribution. The higher mean age at diagnosis compared to other populations could indicate a delay in seeking appropriate care. The Lebanese RA registry provides valuable data on pharmacological interventions used and an opportunity to follow up to examine the effectiveness of different therapeutics and to monitor their side effects.
Keywords: AUBMC; Lebanon; RA Registry; biologic agents; rheumatoid Arthritis.
© 2022 The Mediterranean Journal of Rheumatology (MJR).
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29. Clin Rheumatol. 2019. PMID: 31353421
-
Clinical profile of 266 Filipino patients with rheumatoid arthritis included in the rheumatoid arthritis database and registry (RADAR) of the Philippine General Hospital.Int J Rheum Dis. 2015 May;18(4):433-8. doi: 10.1111/1756-185X.12273. Epub 2014 Feb 7. Int J Rheum Dis. 2015. PMID: 26010598
-
Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.Arthritis Res Ther. 2021 Sep 8;23(1):236. doi: 10.1186/s13075-021-02599-4. Arthritis Res Ther. 2021. PMID: 34496952 Free PMC article.
-
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3. Cochrane Database Syst Rev. 2019. PMID: 31125448 Free PMC article.
-
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7. Pharmacoeconomics. 2018. PMID: 29882210 Review.
Cited by
-
Cannabinoid Receptor 2 Gene Polymorphism and the Risk of Developing Rheumatoid Arthritis in Lebanese Patients.Cannabis Cannabinoid Res. 2024 Dec;9(6):e1597-e1603. doi: 10.1089/can.2023.0220. Epub 2024 Mar 18. Cannabis Cannabinoid Res. 2024. PMID: 38498014
References
-
- Turesson C. Swiss Med Wkly 2016. Apr 5;146:w14290. - PubMed
-
- Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008. Jan;58(1):15–25. - PubMed
-
- Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford) 2010. Aug;49(8):1563–9. - PubMed
-
- Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013. Aug;72(8):1315–20. - PMC - PubMed
-
- Chaaya M, Slim ZN, Habib RR, Arayssi T, Dana R, Hamdan O, et al. High burden of rheumatic diseases in Lebanon: a COPCORD study. Int J Rheum Dis 2012. Apr;15(2):136–43. - PubMed
LinkOut - more resources
Full Text Sources